Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

Molecular Immunology

Volumn 46, Issue 14, 2009, Pages 2794-2800

  Gancz, Dana ^a   Fishelson, Zvi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bcl 2; Cancer; CD46; CD55; CD59; Complement; Cytotoxicity; Heat shock proteins; Mortalin

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 7 HYDROXYSTAUROSPORINE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA GLUCAN; CASEIN KINASE II; CD59 ANTIGEN; CETUXIMAB; DECAY ACCELERATING FACTOR; ENZASTAURIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; IRINOTECAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE COFACTOR PROTEIN; RITUXIMAB; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; TAMOXIFEN; TANESPIMYCIN; TRASTUZUMAB;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; HOST RESISTANCE; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; NEOPLASM; NEUROBLASTOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; C-REACTIVE PROTEIN; COMPLEMENT SYSTEM PROTEINS; HSC70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; PEPTIDE HYDROLASES; PROTEIN KINASES;

EID: 68049135726     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.05.009     Document Type: Review

References (112)

1. Akramiene D., Kondrotas A., Didziapetriene J., and Kevelaitis E. Effects of beta-glucans on the immune system. Medicina (Kaunas) 43 (2007) 597-606
2. Allendorf D.J., Yan J., Ross G.D., Hansen R.D., Baran J.T., Subbarao K., Wang L., and Haribabu B. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J. Immunol. 174 (2005) 7050-7056
3. Ardito C.M., Briggs C.D., and Crawford H.C. Targeting of extracellular proteases required for the progression of pancreatic cancer. Expert Opin. Ther. Targets 12 (2008) 605-619
4. Attali G., Gancz D., and Fishelson Z. Increased sensitivity of early apoptotic cells to complement-mediated lysis. Eur. J. Immunol. 34 (2004) 3236-3245
5. Bjorge L., Hakulinen J., Vintermyr O.K., Jarva H., Jensen T.S., Iversen O.E., and Meri S. Ascitic complement system in ovarian cancer. Br. J. Cancer 92 (2005) 895-905
6. Blok V.T., Gelderman K.A., Tijsma O.H., Daha M.R., and Gorter A. Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand. J. Immunol. 57 (2003) 591-599
7. Bohana-Kashtan O., Pinna L.A., and Fishelson Z. Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis. Eur. J. Immunol. 35 (2005) 1939-1948
8. Budzko D.B., Lachmann P.J., and McConnell I. Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol. 22 (1976) 98-109
9. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 5 (2004) 981-986
10. Congy-Jolivet N., Probst A., Watier H., and Thibault G. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit. Rev. Oncol. Hematol. 64 (2007) 226-233
11. Contreras J.L., Bilbao G., Smyth C., Eckhoff D.E., Xiang X.L., Jenkins S., Cartner S., Curiel D.T., Thomas F.T., and Thomas J.M. Gene transfer of the Bcl-2 gene confers cytoprotection to isolated adult porcine pancreatic islets exposed to xenoreactive antibodies and complement. Surgery 130 (2001) 166-174
12. Cragg M.S., and Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004) 2738-2743
13. Dall'Acqua W.F., Cook K.E., Damschroder M.M., Woods R.M., and Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177 (2006) 1129-1138
14. Dalle S., Thieblemont C., Thomas L., and Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med. Chem. 8 (2008) 523-532
15. de Fougerolles A.R. Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 19 (2008) 125-132
16. Dechant M., Weisner W., Berger S., Peipp M., Beyer T., Schneider-Merck T., Lammerts van Bueren J.J., Bleeker W.K., Parren P.W., van de Winkel J.G., and Valerius T. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 68 (2008) 4998-5003
17. Donin N., Jurianz K., Ziporen L., Schultz S., Kirschfink M., and Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol. 131 (2003) 254-263
18. Donnelly A., and Blagg B.S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15 (2008) 2702-2717
19. Dundas S.R., Lawrie L.C., Rooney P.H., and Murray G.I. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J. Pathol. 205 (2005) 74-81
20. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002) 161-174
21. Fishelson Z., Donin N., Zell S., Schultz S., and Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40 (2003) 109-123
22. Fishelson Z., Hochman I., Greene L.E., and Eisenberg E. Contribution of heat shock proteins to cell protection from complement-mediated lysis. Int. Immunol. 13 (2001) 983-991
23. Fishelson Z., Kopf E., Paas Y., Ross L., and Reiter Y. Protein phosphorylation as a mechanism of resistance against complement damage. In: Melchers F., et al. (Ed). Progress in Immunology vol. 7 (1989), Springer-Verlag, Berlin 205-208
24. Frade R., Rousselet N., and Jean D. Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. Cancer Gene Ther. 15 (2008) 591-604
25. Gancz D., Donin N., and Fishelson Z. Involvement of the c-jun N-terminal kinase in complement-mediated cell death. Mol. Immunol. 45 (2008) 4139 (abstract)
26. Garrido C., Gurbuxani S., Ravagnan L., and Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem. Biophys. Res. Commun. 286 (2001) 433-442
27. Gelderman K.A., Lam S., Sier C.F., and Gorter A. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity. Eur. J. Immunol. 36 (2006) 977-984
28. Gelderman K.A., Tomlinson S., Ross G.D., and Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25 (2004) 158-164
29. Glennie M.J., French R.R., Cragg M.S., and Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44 (2007) 3823-3837
30. Golay J., Cittera E., Di Gaetano N., Manganini M., Mosca M., Nebuloni M., van Rooijen N., Vago L., and Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91 (2006) 176-183
31. Golay J., Manganini M., Rambaldi A., and Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 89 (2004) 1476-1483
32. Gorter A., and Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today 20 (1999) 576-582
33. Hale G., Swirsky D.M., Hayhoe F.G., and Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol. Biol. Med. 1 (1983) 321-334
34. Heidtmann H.H., Salge U., Havemann K., Kirschke H., and Wiederanders B. Secretion of a latent, acid activatable cathepsin L precursor by human non-small cell lung cancer cell lines. Oncol. Res. 5 (1993) 441-451
35. Hong F., Yan J., Baran J.T., Allendorf D.J., Hansen R.D., Ostroff G.R., Xing P.X., Cheung N.K., and Ross G.D. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173 (2004) 797-806
36. Howard J., and Hughes-Jones N. Complement-mediated lysis with monoclonal antibodies. Prog. Allergy 45 (1988) 1-15
37. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., and Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12 (2006) 682-687
38. Hussain S.R., Cheney C.M., Johnson A.J., Lin T.S., Grever M.R., Caligiuri M.A., Lucas D.M., and Byrd J.C. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin. Cancer Res. 13 (2007) 2144-2150
39. Hyc A., Osiecka-Iwan A., Strzelczyk P., and Moskalewski S. Effect of IL-1beta, TNF-alpha and IL-4 on complement regulatory protein mRNA expression in human articular chondrocytes. Int. J. Mol. Med. 11 (2003) 91-94
40. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2 (2002) 277-288
41. Ishida Y., Yamashita K., Sasaki H., Takajou I., Kubuki Y., Morishita K., Tsubouchi H., and Okayama A. Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry. Cancer Lett. 271 (2008) 167-177
42. Jacobsen F. Increase of the in vitro complement-dependent cytotoxicity against autologous invasive human bladder tumor cells by neuraminidase treatment. Acta. Pathol. Microbiol. Immunol. Scand. [C] 90 (1982) 187-192
43. Jean D., Hermann J., Rodrigues-Lima F., Barel M., Balbo M., and Frade R. Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L. Biochem. J. 312 Pt 3 (1995) 961-969
44. Jimeno A., Rudek M.A., Purcell T., Laheru D.A., Messersmith W.A., Dancey J., Carducci M.A., Baker S.D., Hidalgo M., and Donehower R.C. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother. Pharmacol. 61 (2008) 423-433
45. Jurianz K., Ziegler S., Donin N., Reiter Y., Fishelson Z., and Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int. J. Cancer 93 (2001) 848-854
46. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., and Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. 36 (1999) 929-939
47. Kalmar B., and Greensmith L. Induction of heat shock proteins for protection against oxidative stress. Adv. Drug Deliv. Rev. 61 (2009) 310-318
48. Kemper C., and Atkinson J.P. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7 (2007) 9-18
49. Kennedy A.D., Solga M.D., Schuman T.A., Chi A.W., Lindorfer M.A., Sutherland W.M., Foley P.L., and Taylor R.P. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101 (2003) 1071-1079
50. Kim D.Y., Martin C.B., Lee S.N., and Martin B.K. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle. Cancer Immunol. Immunother. 54 (2005) 1026-1037
51. Klein E., Di Renzo L., and Yefenof E. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol. Immunol. 27 (1990) 1343-1347
52. Korbelik M., and Cecic I. Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. J. Photochem. Photobiol. B 93 (2008) 53-59
53. Kraus S., and Fishelson Z. Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Eur. J. Immunol. 30 (2000) 1272-1280
54. Kraus S., Seger R., and Fishelson Z. Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin. Exp. Immunol. 123 (2001) 366-374
55. Lauf P.K. Immunological and physiological characteristics of the rapid immune hemolysis of neuraminidase-treated sheep red cells produced by fresh guinea pig serum. J. Exp. Med. 142 (1975) 974-988
56. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., and Dahiyat B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4005-4010
57. Loberg R.D., Day L.L., Dunn R., Kalikin L.M., and Pienta K.J. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8 (2006) 69-78
58. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol. 25 (2007) 390-394
59. Macor P., Tripodo C., Zorzet S., Piovan E., Bossi F., Marzari R., Amadori A., and Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 67 (2007) 10556-10563
60. Maison C.M., Villiers C.L., and Colomb M.G. Proteolysis of C3 on U937 cell plasma membranes. Purification of cathepsin G. J. Immunol. 147 (1991) 921-926
61. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., and Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 9 (2008) 1225-1235
62. Masarwa M., Donin N., Ziporen L., and Fishelson Z. Silencing of the mitochondrial hsp70 Mortalin as an adjuvant cancer therapy. Mol. Immunol. 45 (2008) 4104-4105 (abstract)
63. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., and Lachmann P.J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71 (1990) 1-9
64. Modak S., Koehne G., Vickers A., O'Reilly R.J., and Cheung N.K. Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3), (1 → 4)-d-beta-glucan. Leuk. Res. 29 (2005) 679-683
65. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., Cropp G.F., Johnson R.G., Hannah A.L., and Hudis C.A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 25 (2007) 5410-5417
66. Morgan B.P., Dankert J.R., and Esser A.F. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J. Immunol. 138 (1987) 246-253
67. Muller-Eberhard H.J. The membrane attack complex of complement. Annu. Rev. Immunol. 4 (1986) 503-528
68. Odening K.E., Li W., Rutz R., Laufs S., Fruehauf S., Fishelson Z., and Kirschfink M. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin. Exp. Immunol. 155 (2009) 239-248
69. Oh Y., Herbst R.S., Burris H., Cleverly A., Musib L., Lahn M., and Bepler G. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J. Clin. Oncol. 26 (2008) 1135-1141
70. Okroj M., Corrales L., Stokowska A., Pio R., and Blom A.M. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol. Immunother. (2009) Published online: 4 March 2009
71. Ollert M.W., Frade R., Fiandino A., Panneerselvam M., Petrella E.C., Barel M., Pangburn M.K., Bredehorst R., and Vogel C.W. C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells. J. Immunol. 144 (1990) 3862-3867
72. Overall C.M., and Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94 (2006) 941-946
73. Paas Y., Bohana-Kashtan O., and Fishelson Z. Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells. Immunopharmacology 42 (1999) 175-185
74. Paas Y., and Fishelson Z. Shedding of tyrosine and serine/threonine ecto-protein kinases from human leukemic cells. Arch. Biochem. Biophys. 316 (1995) 780-788
75. Pangburn M.K., and Muller-Eberhard H.J. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 2416-2420
76. Pilzer D., and Fishelson Z. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int. Immunol. 17 (2005) 1239-1248
77. Pilzer D., and Fishelson Z. Role for mortalin-C9 interactions in cell resistance to complement-mediated lysis. Mol. Immunol. 44 (2007) 229 (abstract)
78. Powers M.V., Clarke P.A., and Workman P. Death by chaperone: HSP90, HSP70 or both?. Cell Cycle 8 (2009) 518-526
79. Ramanarayanan J., Hernandez-Ilizaliturri F.J., Chanan-Khan A., and Czuczman M.S. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br. J. Haematol. 127 (2004) 519-530
80. Reiter Y., Ciobotariu A., and Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur. J. Immunol. 22 (1992) 1207-1213
81. Ross G.D. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein. Crit. Rev. Immunol. 20 (2000) 197-222
82. Rousselet N., Mills L., Jean D., Tellez C., Bar-Eli M., and Frade R. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 64 (2004) 146-151
83. Rozanov D.V., Savinov A.Y., Golubkov V.S., Tomlinson S., and Strongin A.Y. Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res. 66 (2006) 6258-6263
84. Rushmere N.K., Knowlden J.M., Gee J.M., Harper M.E., Robertson J.F., Morgan B.P., and Nicholson R.I. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int. J. Cancer 108 (2004) 930-936
85. Sawada M., Moriya S., Saito S., Shineha R., Satomi S., Yamori T., Tsuruo T., Kannagi R., and Miyagi T. Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int. J. Cancer 97 (2002) 180-185
86. Schmidt R.E., and Gessner J.E. Fc receptors and their interaction with complement in autoimmunity. Immunol. Lett. 100 (2005) 56-67
87. Sherman M., and Multhoff G. Heat shock proteins in cancer. Ann. N. Y. Acad. Sci. 1113 (2007) 192-201
88. Sier C.F., Gelderman K.A., Prins F.A., and Gorter A. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int. J. Cancer 109 (2004) 900-908
89. Smith M.R., Jin F., and Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Mol. Cancer Ther. 3 (2004) 1693-1699
90. Solit D.B., Osman I., Polsky D., Panageas K.S., Daud A., Goydos J.S., Teitcher J., Wolchok J.D., Germino F.J., Krown S.E., Coit D., Rosen N., and Chapman P.B. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 14 (2008) 8302-8307
91. Spiller O.B., Criado-Garcia O., Rodriguez De Cordoba S., and Morgan B.P. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 121 (2000) 234-241
92. Sreedhar A.S., Nardai G., and Csermely P. Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors. Immunol. Lett. 92 (2004) 157-161
93. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2 (2002) 185-194
94. Stern M., and Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 54 (2005) 11-29
95. Takei K., Yamazaki T., Sawada U., Ishizuka H., and Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk. Res. 30 (2006) 625-631
96. Taldone T., Gozman A., Maharaj R., and Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8 (2008) 370-374
97. Terui Y., Sakurai T., Mishima Y., Mishima Y., Sugimura N., Sasaoka C., Kojima K., Yokoyama M., Mizunuma N., Takahashi S., Ito Y., and Hatake K. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci. 97 (2006) 72-79
98. Tse A.N., Klimstra D.S., Gonen M., Shah M., Sheikh T., Sikorski R., Carvajal R., Mui J., Tipian C., O'Reilly E., Chung K., Maki R., Lefkowitz R., Brown K., Manova-Todorova K., Wu N., Egorin M.J., Kelsen D., and Schwartz G.K. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin. Cancer Res. 14 (2008) 6704-6711
99. Turianskyj F.H., and Gyenes L. The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes. Transplantation 22 (1976) 24-30
100. Uemura T., Shiozaki K., Yamaguchi K., Miyazaki S., Satomi S., Kato K., Sakuraba H., and Miyagi T. Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene 28 (2009) 1218-1229
101. van Lookeren Campagne M., Wiesmann C., and Brown E.J. Macrophage complement receptors and pathogen clearance. Cell Microbiol. 9 (2007) 2095-2102
102. Varela J.C., Atkinson C., Woolson R., Keane T.E., and Tomlinson S. Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int. J. Cancer 123 (2008) 1357-1363
103. Wadhwa R., Sugihara T., Yoshida A., Nomura H., Reddel R.R., Simpson R., Maruta H., and Kaul S.C. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 60 (2000) 6818-6821
104. Wadhwa R., Takano S., Kaur K., Deocaris C.C., Pereira-Smith O.M., Reddel R.R., and Kaul S.C. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int. J. Cancer 118 (2006) 2973-2980
105. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 344 (2001) 1058-1066
106. Watson N.F., Durrant L.G., Madjd Z., Ellis I.O., Scholefield J.H., and Spendlove I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol. Immunother. 55 (2006) 973-980
107. Xu C., Jung M., Burkhardt M., Stephan C., Schnorr D., Loening S., Jung K., Dietel M., and Kristiansen G. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 62 (2005) 224-232
108. Yan J., Allendorf D.J., Li B., Yan R., Hansen R., and Donev R. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv. Exp. Med. Biol. 632 (2008) 159-174
109. Zell S., Geis N., Rutz R., Schultz S., Giese T., and Kirschfink M. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol. 150 (2007) 576-584
110. Zhivotovsky B., and Orrenius S. Defects in the apoptotic machinery of cancer cells: role in drug resistance. Semin. Cancer Biol. 13 (2003) 125-134
111. Ziller F., Macor P., Bulla R., Sblattero D., Marzari R., and Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 35 (2005) 2175-2183
112. Ziporen L., Donin N., Shmushkovich T., Gross A., and Fishelson Z. Programmed necrotic cell death induced by complement involves a Bid-dependent pathway. J. Immunol. 182 (2009) 515-521